Immunotherapy for Alzheimer's disease

被引：137

作者：

Gelinas, DS

DaSilva, K

Fenili, D

George-Hyslop, PS

McLaurin, J

机构：

[1] Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada

[2] Univ Toronto, Dept Lab Med, Toronto, ON M5S 3H2, Canada

[3] Univ Toronto, Dept Pathobiol, Toronto, ON M5S 3H2, Canada

[4] Univ Toronto, Dept Med, Toronto, ON M5S 3H2, Canada

来源：

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA | 2004年 / 101卷

关键词：

D O I：

10.1073/pnas.0404866101

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The utility of vaccine strategies to treat neurodegenerative diseases such as Alzheimer's disease (AD) may still hold promise. Both active and passive immunization strategies reduced AD-like pathology and restored cognitive deficits in transgenic mice. These results were initially met with considerable optimism; however, phase IIa clinical trials were halted because of a small but significant occurrence of meningoencephalitis. Knowledge gained from studies on amyloid-beta peptide (Abeta) immunotherapy will allow optimization of new-generation vaccines, targeting highly specific epitopes while reducing undesired side effects. In harnessing and steering the immune system, an effective response can be generated against Abeta. If this proves successful, Abeta vaccination could provide the first definitive treatment for AD.

引用

页码：14657 / 14662

页数：6

共 74 条

[41]

McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO

[42]

2-M

[43] Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid β-peptide presentation to Th1 cells [J].